BIO-RAD LABORATORIES, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Bio-Rad reported Q2 2026 revenue of $651.0M (flat YoY), with Life Science declining 4.1% and Clinical Diagnostics growing 2.6%. GAAP net income $371.4M ($13.85/share, diluted; 26.8M shares) was boosted by a $458M gain on Sartorius AG equity securities; non-GAAP net income was $70.2M ($2.62/share). The company generated $99M operating cash flow and repurchased $32M shares. Full-year 2026 guidance reaffirmed: currency-neutral revenue decline of 3.0% to growth of 0.5%, with non-GAAP operating margin 10.0–12.0%.
Why this rating
Flat operational revenue with offsetting segment trends; guidance reiterated. Material Sartorius gain inflates GAAP earnings but non-GAAP shows margin compression. Near-term business trajectory unchanged.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.